09:52 AM EDT, 05/12/2025 (MT Newswires) -- Liquidia ( LQDA ) said Monday that United Therapeutics ( UTHR ) has filed a complaint Friday accusing the company of infringing United's patent.

The complaint, filed in the US District Court for the Middle District of North Carolina, also seeks to enjoin Liquidia ( LQDA ) from commercializing Yutrepia, or treprostinil inhalation power, if the US Food and Drug Administration approves it for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Liquidia ( LQDA ) Chief Executive Roger Jeffs said the company has previously invalidated similar claims covering the treatment of pulmonary hypertension patients with inhaled treprostinil.

The company said United Therapeutics ( UTHR ) is not currently seeking an injunction against the FDA, which had set a Prescription Drug User Fee Act goal date of May 24 to prevent final approval of the new drug application for Yutrepia.

United Therapeutics ( UTHR ) did not immediately respond to a request for comment from MT Newswires.

Price: 15.46, Change: +0.20, Percent Change: +1.31